When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?
How are you incorporating CONTACT-03 data presented at #ASCO2023 (Pal et al., PMID 37290461) into your practice? Would you consider immunotherapy re-challenge for someone on adjuvant pembrolizumab? What about for someone whose last immunotherapy exposure was >1 year ago?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The University of Texas Health Science Center at San Antonio
Answered on
Checkpoint inhibitors combinations (IO/IO and TKI/IO) are the most likely way for a patient to experience a durable response. However, we need better treatment options for patients who are experiencing disease progression to these therapies. A number of new immune treatments are currently in clinica...
Join for free or sign in to see the full answer